Condition: Bronchiolitis Obliterans Syndrome (BOS) after Hematopoietic Cell Transplantation (HCT)
Journal: Transplantation and cellular therapy
Treatment Used: Montelukast
Number of Patients: 25
Published: February 03, 2022
Summary: Prospective Phase II Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bronchiolitis Obliterans Syndrome Pathogenesis.
Summary: Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution.